Miraculins, Cachet Pharmaceutical Co. Ltd. deal

Miraculins and Cachet, which is majority state-owned, signed a letter of intent to negotiate Cachet's acquisition of an exclusive license to commercialize Miraculins' SCOUT DS Non-Invasive Diabetes Screening technology in China. Miraculins said the letter of intent gives the parties 90 days from Sept. 30 to establish and execute a definitive licensing agreement, which Miraculins said may include an upfront payment, royalties, funding for regulatory approval and a commitment to conduct and fund market development activities. ...